What is a stock summary page? Click here for an overview.
Business Description
Ionis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US4622221004
Compare
Compare
Traded in other countries / regions
IONS.USAIONS.Mexico0JDI.UKISI.Germany Index Membership
Russell 1000Russell 3000 IPO Date
1991-05-17Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.62 | |||||
| Equity-to-Asset | 0.2 | |||||
| Debt-to-Equity | 2.41 | |||||
| Debt-to-EBITDA | -4.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.77 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -6.4 | |||||
| 3-Year EBITDA Growth Rate | -299.9 | |||||
| 3-Year EPS without NRI Growth Rate | -152 | |||||
| 3-Year Book Growth Rate | -12 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.19 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 19.41 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.45 | |||||
| 9-Day RSI | 27.07 | |||||
| 14-Day RSI | 31.58 | |||||
| 3-1 Month Momentum % | -5.34 | |||||
| 6-1 Month Momentum % | -13.08 | |||||
| 12-1 Month Momentum % | -23.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.47 | |||||
| Quick Ratio | 8.43 | |||||
| Cash Ratio | 7.43 | |||||
| Days Inventory | 698.93 | |||||
| Days Payable | 653.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.8 | |||||
| Shareholder Yield % | -12.1 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.41 | |||||
| Operating Margin % | -67.37 | |||||
| Net Margin % | -64.37 | |||||
| FCF Margin % | -78.18 | |||||
| ROE % | -103.27 | |||||
| ROA % | -15.62 | |||||
| ROIC % | -83.34 | |||||
| 3-Year ROIIC % | -307.17 | |||||
| ROC (Joel Greenblatt) % | -151.99 | |||||
| ROCE % | -14.58 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.76 | |||||
| PB Ratio | 7.27 | |||||
| Price-to-Tangible-Book | 7.27 | |||||
| EV-to-EBIT | -9.15 | |||||
| EV-to-Forward-EBIT | -6.42 | |||||
| EV-to-EBITDA | -9.72 | |||||
| EV-to-Forward-EBITDA | -6.66 | |||||
| EV-to-Revenue | 4.86 | |||||
| EV-to-Forward-Revenue | 5.14 | |||||
| EV-to-FCF | -6.21 | |||||
| Price-to-GF-Value | 0.78 | |||||
| Price-to-Median-PS-Value | 0.55 | |||||
| Price-to-Net-Current-Asset-Value | 20.84 | |||||
| Earnings Yield (Greenblatt) % | -10.93 | |||||
| FCF Yield % | -12.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IONS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ionis Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 705.137 | ||
| EPS (TTM) ($) | -3.04 | ||
| Beta | 0.01 | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 37.35 | ||
| 14-Day RSI | 31.58 | ||
| 14-Day ATR ($) | 1.451919 | ||
| 20-Day SMA ($) | 31.628 | ||
| 12-1 Month Momentum % | -23.07 | ||
| 52-Week Range ($) | 26.875 - 52.34 | ||
| Shares Outstanding (Mil) | 158.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ionis Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ionis Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ionis Pharmaceuticals Inc Frequently Asked Questions
What is Ionis Pharmaceuticals Inc(IONS)'s stock price today?
The current price of IONS is $27.09. The 52 week high of IONS is $52.34 and 52 week low is $26.88.
When is next earnings date of Ionis Pharmaceuticals Inc(IONS)?
The next earnings date of Ionis Pharmaceuticals Inc(IONS) is 2025-05-07 Est..
Does Ionis Pharmaceuticals Inc(IONS) pay dividends? If so, how much?
Ionis Pharmaceuticals Inc(IONS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers